ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS

saveria capria, silvia maria trisolini, clara minotti, caterina stefanizzi, luisa cardarelli, Martina Canichella, claudio cartoni, daniela diverio, maria stefania de propris, marco mancini, alessandra micozzi, robin foà, giovanna meloni
  • silvia maria trisolini
    Sapienza Università di Roma, Italy
  • clara minotti
    Sapienza Università di Roma, Italy
  • caterina stefanizzi
    Sapienza Università di Roma, Italy
  • luisa cardarelli
    Sapienza Università di Roma, Italy
  • Martina Canichella
    Affiliation not present
  • claudio cartoni
    Sapienza Università di Roma, Italy
  • daniela diverio
    Sapienza Università di Roma, Italy
  • maria stefania de propris
    Sapienza Università di Roma, Italy
  • marco mancini
    Sapienza Università di Roma, Italy
  • alessandra micozzi
    Sapienza Università di Roma,
  • robin foà
    Sapienza Università di Roma, Italy
  • giovanna meloni
    Sapienza Università di Roma, Italy

Abstract

Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation.

We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant.

Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.

Keywords

Leukemia; Gentuzumab Ozogamicin; Allogeneic stem cell transplantation

Full Text:

PDF
HTML
Submitted: 2014-06-13 09:32:12
Published: 2012-11-06 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
183

Views:
PDF
122
HTML
511

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185